Murphy III JT, Terveen DC, Aminlari AE, Dhamdhere K, Dickerson Jr JE. Clin Ophthalmol. 2022;16:3043–3052
On page 3043, the second sentence of the Introduction, “The study was the basis of the FDA approved OSS indication to “reduce IOP in adult patients with open-angle glaucoma”.” should read “The study was the basis of the FDA cleared OSS indication to “reduce IOP in adult patients with primary open-angle glaucoma”.”
The authors apologize for this error and advise it does not affect the results of the paper.